Follow us on:

Linkedin Facebook

Halma plc 20.1% Potential Decrease Indicated by JP Morgan Cazenove

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Halma plc using EPIC/TICKER code (LON:HLMA) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘UNDERWEIGHT’ this morning by analysts at JP Morgan Cazenove. Halma plc are listed in the Industrials sector within UK Main Market. JP Morgan Cazenove have set their target price at 1500 GBX on its stock. This now indicates the analyst believes there is a potential downside of -20.1% from the opening price of 1876.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 124.5 points and decreased 113.5 points respectively. The 1 year high for the share price is 2099 GBX while the year low stock price is currently 1215 GBX.

Halma plc has a 50 day moving average of 1,981.82 GBX and the 200 Day Moving Average price is recorded at 1,803.04. There are currently 379,645,332 shares in issue with the average daily volume traded being 1,010,202. Market capitalisation for LON:HLMA is £7,211,362,473 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Halma plc

    Halma Plc CFO Steve Gunning to retire, Carole Cran appointed as CFO Designate

    Halma plc announces CFO transition with Steve Gunning retiring in 2025 and Carole Cran stepping in, continuing the company's growth strategy.
    Broker Ratings

    Halma plc -4.1% potential downside indicated by JP Morgan Cazenove

    Broker Ratings

    Halma plc -5.9% potential downside indicated by JP Morgan

    Halma plc

    Halma plc achieves record H1 results, continued dividend growth

    Halma plc (LON:HLMA) reports strong half-year results, announcing a 7% interim dividend increase, boosting shareholder returns in 2024.
    Halma plc

    Halma Plc acquires Lamidey Noury, enhancing minimally invasive surgical solutions

    Halma Plc acquires Lamidey Noury Medical, expanding its healthcare portfolio with advanced electrosurgical devices for minimally invasive procedures.
    Broker Ratings

    Halma plc -11.6% potential downside indicated by Deutsche

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.